Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01867671 · ClinicalTrials.gov registry record · Phase 2
Peanut Oral Immunotherapy in Children
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT01867671 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 146 participants.
The verdict
NCT01867671, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multi-center study comparing peanut oral immunotherapy (OIT) to placebo in the induction of tolerance and desensitization in peanut-allergic children. Eligible participants with peanut allergy will be randomly assigned to receive either peanut OIT or placebo for 134 weeks followed by peanut avoidance for 26 weeks.
Interventions
- BIOLOGICAL Peanut Oral Immunotherapy - Liquid Extract
- BIOLOGICAL Placebo for Peanut Oral Immunotherapy - Liquid Extract form
- BIOLOGICAL Peanut Oral Immunotherapy - Peanut Flour
- BIOLOGICAL Placebo for Peanut Oral Immunotherapy - Peanut Flour
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2013-08-13 |
| Est. Completion | 2018-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01867671
The ClinicalTrials.gov registry entry for NCT01867671 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Peanut Oral Immunotherapy - Liquid Extract is the first listed.
NCT01867671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01867671 about?
NCT01867671 is a clinical study titled "Peanut Oral Immunotherapy in Children". This is a randomized, double-blind, placebo-controlled, multi-center study comparing peanut oral immunotherapy (OIT) to placebo in the induction of tolerance and desensitization in peanut-allergic children. Eligible participants with peanut allergy will be randomly assigned to receive either peanut ...
What is the current status of trial NCT01867671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2013-08-13. Estimated completion is 2018-12-21.
What interventions are being tested in trial NCT01867671?
The interventions under investigation include: Peanut Oral Immunotherapy - Liquid Extract (BIOLOGICAL), Placebo for Peanut Oral Immunotherapy - Liquid Extract form (BIOLOGICAL), Peanut Oral Immunotherapy - Peanut Flour (BIOLOGICAL), Placebo for Peanut Oral Immunotherapy - Peanut Flour (BIOLOGICAL).
Who is sponsoring clinical trial NCT01867671?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.